Xenia Jimenez
About
In The Last Decade
Xenia Jimenez
27 papers receiving 1.6k citations
Peers
Comparison fields: 5 of 82
- Molecular Biology 1.2k
- Oncology 670
- Radiology, Nuclear Medicine and Imaging 630
- Cancer Research 280
- Pulmonary and Respiratory Medicine 227
Countries citing papers authored by Xenia Jimenez
This map shows the geographic impact of Xenia Jimenez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xenia Jimenez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xenia Jimenez more than expected).
Fields of papers citing papers by Xenia Jimenez
This network shows the impact of papers produced by Xenia Jimenez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xenia Jimenez. The network helps show where Xenia Jimenez may publish in the future.
Co-authorship network of co-authors of Xenia Jimenez
This figure shows the co-authorship network connecting the top 25 collaborators of Xenia Jimenez. A scholar is included among the top collaborators of Xenia Jimenez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xenia Jimenez. Xenia Jimenez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Abstract #844: Anti-TGF beta receptor II antibody suppresses tumor growth and metastasis through inhibiting TGF beta autocrine stimulation of tumor cells and myeloid cells | 1 |
| 2 | 50 | |
| 3 | 32 | |
| 4 | 79 | |
| 5 | 39 | |
| 6 | 23 | |
| 7 | 18 | |
| 8 | Identification and characterization of a fully human antibody directed against epidermal growth factor receptor for cancer therapy | 14 |
| 9 | 98 | |
| 10 | 27 | |
| 11 | A fully human monoclonal antibody against VEGFR-1 inhibits growth of human breast cancers | 1 |
| 12 | 52 | |
| 13 | 156 | |
| 14 | 31 | |
| 15 | 131 | |
| 16 | 27 | |
| 17 | 122 | |
| 18 | Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor. | 40 |
| 19 | 29 | |
| 20 | 43 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.